A Study of MEDI-575 in Patients with Advanced Solid Malignancies

Study identifier:D2840C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients with Advanced Solid Malignancies

Medical condition

Advanced solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

MEDI-575

Sex

All

Actual Enrollment

23

Study type

Interventional

Age

20 Years - 150 Years

Date

Study Start Date: 01 Mar 2010
Primary Completion Date: 01 Nov 2012
Study Completion Date: 01 Nov 2012

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2014 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

MedImmune

Inclusion and exclusion criteria